APO RESEARCH · REPORT
RNAi for Therapeutic
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Product & engineering
Understand the product.
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Selected research
Industry Growth & Trends
Global RNAi for Therapeutic Industry Growth and Trends Forecast to 2032
Market perspective
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
According to APO Research, the global RNAi for Therapeutic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Report Scope
Read the full market overview
This report provides a structured, data-driven view of the global RNAi for Therapeutic market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The RNAi for Therapeutic market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global RNAi for Therapeutic market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to RNAi for Therapeutic.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global RNAi for Therapeutic market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
RNAi for Therapeutic Market by Company
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
RNAi for Therapeutic Segment by Type
siRNA
miRNA
shRNA
RNAi for Therapeutic Segment by Application
Cancer
Cardiovascular
HBV
Others
RNAi for Therapeutic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNAi for Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of RNAi for Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNAi for Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of RNAi for Therapeutic companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- siRNA
- miRNA
- shRNA
Applications
- Cancer
- Cardiovascular
- HBV
- Others
Companies covered
- Alnylam Pharmaceuticals
- Arbutus Biopharma (Tekmira)
- Arrowhead
- Dicerna Pharmaceuticals
- Mirna Therapeutics
- Quark Pharmaceuticals
- RXi Pharmaceuticals
- Silence Therapeutics
- Benitec Biopharma
- miRagen Therapeutics
- Sylentis
- Gradalis
- Sirnaomics
- Silenseed
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global RNAi for Therapeutic Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global RNAi for Therapeutic Market Size by Region (2021-2032)
- 1.4.1 Global RNAi for Therapeutic Market Size by Region (2021-2026)
- 1.4.2 Global RNAi for Therapeutic Market Size by Region (2027-2032)
- 1.5 Key Regions RNAi for Therapeutic Market Size (2021-2032)
- 1.5.1 North America RNAi for Therapeutic Market Size Growth Rate (2021-2032)
- 1.5.2 Europe RNAi for Therapeutic Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific RNAi for Therapeutic Market Size Growth Rate (2021-2032)
- 1.5.4 South America RNAi for Therapeutic Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa RNAi for Therapeutic Market Size Growth Rate (2021-2032)
2 RNAi for Therapeutic Market by Type
- 2.1 Type Introduction
- 2.1.1 siRNA
- 2.1.2 miRNA
- 2.1.3 shRNA
- 2.2 Global RNAi for Therapeutic Market Size by Type
- 2.2.1 Global RNAi for Therapeutic Market Size Overview by Type (2021-2032)
- 2.2.2 Global RNAi for Therapeutic Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global RNAi for Therapeutic Market Size Forecasted by Type (2027-2032)
- 2.3 Global RNAi for Therapeutic Market Size by Regions
- 2.3.1 North America RNAi for Therapeutic Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe RNAi for Therapeutic Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific RNAi for Therapeutic Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America RNAi for Therapeutic Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa RNAi for Therapeutic Market Size Breakdown by Type (2021-2026)
3 RNAi for Therapeutic Market by Application
- 3.1 Type Introduction
- 3.1.1 Cancer
- 3.1.2 Cardiovascular
- 3.1.3 HBV
- 3.1.4 Others
- 3.2 Global RNAi for Therapeutic Market Size by Application
- 3.2.1 Global RNAi for Therapeutic Market Size Overview by Application (2021-2032)
- 3.2.2 Global RNAi for Therapeutic Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global RNAi for Therapeutic Market Size Forecasted by Application (2027-2032)
- 3.3 Global RNAi for Therapeutic Market Size by Regions
- 3.3.1 North America RNAi for Therapeutic Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe RNAi for Therapeutic Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific RNAi for Therapeutic Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America RNAi for Therapeutic Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa RNAi for Therapeutic Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 RNAi for Therapeutic Industry Trends
- 4.2 RNAi for Therapeutic Industry Drivers
- 4.3 RNAi for Therapeutic Industry Opportunities and Challenges
- 4.4 RNAi for Therapeutic Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by RNAi for Therapeutic Revenue (2021-2026)
- 5.2 Global RNAi for Therapeutic Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global RNAi for Therapeutic Key Company Headquarters & Area Served
- 5.4 Global RNAi for Therapeutic Company, Product Type & Application
- 5.5 Global RNAi for Therapeutic Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global RNAi for Therapeutic Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 RNAi for Therapeutic Players Market Share by Revenue in 2025
- 5.6.3 2025 RNAi for Therapeutic Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Alnylam Pharmaceuticals
- 6.1.1 Alnylam Pharmaceuticals Company Information
- 6.1.2 Alnylam Pharmaceuticals Business Overview
- 6.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Product Portfolio
- 6.1.5 Alnylam Pharmaceuticals Recent Developments
- 6.2 Arbutus Biopharma (Tekmira)
- 6.2.1 Arbutus Biopharma (Tekmira) Company Information
- 6.2.2 Arbutus Biopharma (Tekmira) Business Overview
- 6.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product Portfolio
- 6.2.5 Arbutus Biopharma (Tekmira) Recent Developments
- 6.3 Arrowhead
- 6.3.1 Arrowhead Company Information
- 6.3.2 Arrowhead Business Overview
- 6.3.3 Arrowhead RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Arrowhead RNAi for Therapeutic Product Portfolio
- 6.3.5 Arrowhead Recent Developments
- 6.4 Dicerna Pharmaceuticals
- 6.4.1 Dicerna Pharmaceuticals Company Information
- 6.4.2 Dicerna Pharmaceuticals Business Overview
- 6.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Product Portfolio
- 6.4.5 Dicerna Pharmaceuticals Recent Developments
- 6.5 Mirna Therapeutics
- 6.5.1 Mirna Therapeutics Company Information
- 6.5.2 Mirna Therapeutics Business Overview
- 6.5.3 Mirna Therapeutics RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Mirna Therapeutics RNAi for Therapeutic Product Portfolio
- 6.5.5 Mirna Therapeutics Recent Developments
- 6.6 Quark Pharmaceuticals
- 6.6.1 Quark Pharmaceuticals Company Information
- 6.6.2 Quark Pharmaceuticals Business Overview
- 6.6.3 Quark Pharmaceuticals RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Quark Pharmaceuticals RNAi for Therapeutic Product Portfolio
- 6.6.5 Quark Pharmaceuticals Recent Developments
- 6.7 RXi Pharmaceuticals
- 6.7.1 RXi Pharmaceuticals Company Information
- 6.7.2 RXi Pharmaceuticals Business Overview
- 6.7.3 RXi Pharmaceuticals RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 RXi Pharmaceuticals RNAi for Therapeutic Product Portfolio
- 6.7.5 RXi Pharmaceuticals Recent Developments
- 6.8 Silence Therapeutics
- 6.8.1 Silence Therapeutics Company Information
- 6.8.2 Silence Therapeutics Business Overview
- 6.8.3 Silence Therapeutics RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Silence Therapeutics RNAi for Therapeutic Product Portfolio
- 6.8.5 Silence Therapeutics Recent Developments
- 6.9 Benitec Biopharma
- 6.9.1 Benitec Biopharma Company Information
- 6.9.2 Benitec Biopharma Business Overview
- 6.9.3 Benitec Biopharma RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Benitec Biopharma RNAi for Therapeutic Product Portfolio
- 6.9.5 Benitec Biopharma Recent Developments
- 6.10 miRagen Therapeutics
- 6.10.1 miRagen Therapeutics Company Information
- 6.10.2 miRagen Therapeutics Business Overview
- 6.10.3 miRagen Therapeutics RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 miRagen Therapeutics RNAi for Therapeutic Product Portfolio
- 6.10.5 miRagen Therapeutics Recent Developments
- 6.11 Sylentis
- 6.11.1 Sylentis Company Information
- 6.11.2 Sylentis Business Overview
- 6.11.3 Sylentis RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Sylentis RNAi for Therapeutic Product Portfolio
- 6.11.5 Sylentis Recent Developments
- 6.12 Gradalis
- 6.12.1 Gradalis Company Information
- 6.12.2 Gradalis Business Overview
- 6.12.3 Gradalis RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Gradalis RNAi for Therapeutic Product Portfolio
- 6.12.5 Gradalis Recent Developments
- 6.13 Sirnaomics
- 6.13.1 Sirnaomics Company Information
- 6.13.2 Sirnaomics Business Overview
- 6.13.3 Sirnaomics RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Sirnaomics RNAi for Therapeutic Product Portfolio
- 6.13.5 Sirnaomics Recent Developments
- 6.14 Silenseed
- 6.14.1 Silenseed Company Information
- 6.14.2 Silenseed Business Overview
- 6.14.3 Silenseed RNAi for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Silenseed RNAi for Therapeutic Product Portfolio
- 6.14.5 Silenseed Recent Developments
7 North America
- 7.1 North America RNAi for Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America RNAi for Therapeutic Market Size by Country (2021-2026)
- 7.3 North America RNAi for Therapeutic Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe RNAi for Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe RNAi for Therapeutic Market Size by Country (2021-2026)
- 8.3 Europe RNAi for Therapeutic Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific RNAi for Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific RNAi for Therapeutic Market Size by Country (2021-2026)
- 9.3 Asia-Pacific RNAi for Therapeutic Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America RNAi for Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America RNAi for Therapeutic Market Size by Country (2021-2026)
- 10.3 South America RNAi for Therapeutic Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa RNAi for Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa RNAi for Therapeutic Market Size by Country (2021-2026)
- 11.3 Middle East & Africa RNAi for Therapeutic Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst